| Prev Close | 1.73 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 1.30 / 2.68 |
| Avg Volume | 1.68M |
| Exchange | NASDAQ |
| Shares Outstanding | 243.26M |
| Market Cap | 423.27M |
| EPS | -0.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
How Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss?
Arena Pharmaceuticals (ARNA) posted a wider loss than analysts projected after today's market close.
Arena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug
Arena Pharmaceuticals (ARNA) stock is trading higher after receiving FDA approval for a new extended release weight-loss pill.
Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Strong On High Relative Volume Stock
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate
Eisai Inc. And Arena Pharmaceuticals Announce FDA Approval Of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
Once-a-Day Tablet Offers Millions of Americans a New Option to Address Chronic Weight Management
August 26th Options Now Available For Arena Pharmaceuticals (ARNA)
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the August 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new August 26th contracts and identified the following put contract of particular interest.
Interesting ARNA Call Options For August 5th
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the August 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new August 5th contracts and identified the following call contract of particular interest.
Interesting ARNA Put Options For July 1st
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the July 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new July 1st contracts and identified the following put contract of particular interest.
Arena Pharmaceuticals Announces Appointment Of Amit D. Munshi As President And Chief Executive Officer
- Biopharmaceutical Industry Veteran Brings Over 25 Years of Management and Operational Experience -
Arena Pharma (ARNA) Stock Advancing on Favorable Trial Results
Arena Pharma (ARNA) stock is climbing Tuesday afternoon as the bio-pharmaceutical company announced favorable results from a phase 1b trial for its pain relief drug.
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate
Weak On High Volume: Arena Pharmaceuticals (ARNA)
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
Arena Pharmaceuticals (ARNA) Stock Edges Lower in After-Hours Trading on Q4 Results
Arena Pharmaceuticals (ARNA) stock is inching down in after-hours trading on Monday after the company reported its 2015 fourth quarter results after the closing bell.
Weak On High Volume: Arena Pharmaceuticals (ARNA)
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
Boehringer Ingelheim And Arena Pharmaceuticals Collaborate To Advance Research In Schizophrenia
- Collaboration partners to strengthen research in psychiatric diseases -
Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
Commit To Purchase Arena Pharmaceuticals At $1, Earn 21% Using Options
Investors eyeing a purchase of Arena Pharmaceuticals Inc shares, but cautious about paying the going market price of $1.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $1 strike, which has a bid at the time of this writing of 21 cents.
Strong On High Relative Volume: Arena Pharmaceuticals (ARNA)
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate
First Week of ARNA July 2016 Options Trading
Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the July 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Short Interest Decreases By 11% For ARNA
The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, which shows a 3,212,866 share decrease in total short interest for Arena Pharmaceuticals Inc , to 25,879,900, a decrease of 11.04% since 10/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Arena Pharmaceuticals (ARNA) Stock: Weak On High Volume Today
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
Arena Pharmaceuticals Announces New Strategic Focus And Cost Reduction Plan
- Strategic priorities include clinical-stage pipeline and core research function -
Arena Pharmaceuticals (ARNA) Is Weak On High Volume Today
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate
Commit To Buy Arena Pharmaceuticals At $1.50, Earn 22% Using Options
Investors eyeing a purchase of Arena Pharmaceuticals Inc shares, but tentative about paying the going market price of $2.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $1.50 strike, which has a bid at the time of this writing of 33 cents.
